Cargando…
SUN-448 Giant Prolactinomas: A Follow-Up of 25 Years with Dopamine Agonists
Giant prolactinomas are tumors with a large size > 4 cm and/or prolactin levels higher than 3000 ng/ml and/or highly invasive growth. Today dopamine agonists, mainly cabergoline (CAB), are the first-line choice in the treatment of these tumors. Objective: To assess the efficacy, safety and long-t...
Autores principales: | Mallea Gil, Susana, Diez, Sabrina, Stalldecker, Graciela, Palazzo, Adriana, Sosa, Maria de los Angeles, Telares, Noelia, Peressotti, Bruno, Ballarino, Carolina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553132/ http://dx.doi.org/10.1210/js.2019-SUN-448 |
Ejemplares similares
-
SAT-247 Use of Double Dopamine Agonists in Giant Prolactinomas: A Series of 6 Cases
por: Kuan, Yueh Chien
Publicado: (2020) -
PMON169 D2R Expression in Dopamine-Agonist Resistant Prolactinomas
por: Levine, Alice, et al.
Publicado: (2022) -
SUN-447 Screening of Genetic Alterations in Patients with Giant Prolactinomas
por: Chaves, Carolina, et al.
Publicado: (2019) -
SUN-LB073 Giant Prolactinomas: Recidive (Case Report)
por: Galesanu, Corina
Publicado: (2019) -
SAT-455 Analysis of a Group of Prolactinomas Resistant to Treatment with Dopamine Agonists at a University Hospital in Buenos Aires, Argentina
por: Gonzalez Pernas, Mariana, et al.
Publicado: (2019)